Congenital disorders of glycosylation (CDG) are severe inherited diseases in which aberrant protein glycosylation is a hallmark. From this genetically and clinically heterogenous group, a significant subgroup due to Golgi homeostasis defects is emerging. We previously identified TMEM165 as a Golgi protein involved in CDG. Extremely conserved in the eukaryotic reign, the molecular mechanism by which TMEM165 deficiencies lead to Golgi glycosylation abnormalities is enigmatic. As GDT1 is the ortholog of TMEM165 in yeast, both gdt1Δ null mutant yeasts and TMEM165 depleted cells were used. We highlighted that the observed Golgi glycosylation defects due to Gdt1p/TMEM165 deficiency result from Golgi manganese homeostasis defect. We discovered that in both yeasts and mammalian Gdt1p/TMEM165-deficient cells, Mn 2+ supplementation could restore a normal glycosylation. We also showed that the GPP130 Mn 2+ sensitivity was altered in TMEM165 depleted cells. This study not only provides novel insights into the molecular causes of glycosylation defects observed in TMEM165-deficient cells but also suggest that TMEM165 is a key determinant for the regulation of Golgi Mn 2+ homeostasis.
Introduction
Congenital disorders of glycosylation (CDG) are a rapidly growing disease family due to genetic defects of protein and lipid glycosylation (1) (2) (3) (4) . In protein N-glycosylation, two different CDG groups can be distinguished. In CDG-I, the molecular defects affect the oligosaccharidic precursor assembly pathway in the endoplasmic reticulum, leading to the presence of unoccupied N-glycosylation sites. CDG-II are due to defects in the glycan processing in the Golgi, giving rise to the presence of abnormal glycan structures on glycoproteins (5, 6) . To date, the CDG family comprises nearly hundred disorders (7) . Most are due to defects in the specific glycosylation machinery, such as SLC35A1 [MIM 605634 ], B4GALT1 [MIM 137060 ] and MGAT2 [MIM 602616]) (8) (9) (10) . However, in the CDG-II group, defects have lately been discovered in proteins that are not only involved in glycosylation but also in other cellular functions. Among these are CDG caused by altered vesicular Golgi trafficking and/or Golgi pH homeostasis marking a new era in the CDG field (11) (12) (13) (14) (15) (16) .
In 2012, we reported a novel disorder in this group namely TMEM165-CDG (17) (OMIM entry #614727). These patients present a peculiar phenotype including major skeletal dysplasia and hyposialylation and hypogalactosylation of N-glycosylproteins (17, 18) . TMEM165 is a transmembrane protein of 324 amino acids belonging to a well conserved but uncharacterized family of membrane proteins named UPF0016 (Uncharacterized Protein Family 0016; Pfam PF01169). We demonstrated that TMEM165 is a novel Golgi protein that can also be found in endocytic pathways (late endosomes and lysosomes) (19) . We indirectly demonstrated that defects in TMEM165 affect both cytosolic Ca 2+ and lysosomal pH homeostasis (20) . Based on these results, we then hypothesized that TMEM165 could be a Golgi-localized Ca 2+ /H+ antiporter regulating both Golgi Ca 2+ and pH homeostasis (20) . Extremely conserved in the eukaryotic reign, GDT1 is the yeast ortholog of TMEM165. We showed that the gdt1Δ mutant presents a strong growth defect phenotype in presence of high concentrations of calcium chloride (500-700 m). In yeast, the Ca 2+ Golgi homeostasis mainly results from the activity of Pmr1p, a Golgi P-type ATPase essential to import Ca 2+ but also Mn 2+ in the Golgi lumen (21) (22) (23) . Its activity then maintains very low Ca 2+ and Mn 2+ concentrations into the cytosol. Interestingly, it has been shown that Pmr1 inactivation leads to strong Golgi glycosylation and trafficking defects (24) . The aim of this study is to decipher the molecular mechanism by which a lack of TMEM165 affects Golgi glycosylation. We used gdt1 null mutant yeasts and TMEM165 depleted mammalian cells to unravel this mechanism, and present evidence that in both yeasts and mammalian cells, the Golgi glycosylation defects due to a lack of Gdt1p/TMEM165, result from defective Golgi manganese homeostasis.
Results

Mn
2+ suppresses the Golgi glycosylation defect of gdt1Δ null mutants cultured in presence of high Ca 2+ concentrations
We previously reported that gdt1Δ null mutants presented a strong growth defect in the presence of high calcium chloride concentrations such as 700 m (25) . To assess whether this growth deficiency was correlated to an abnormal N-linked glycosylation, the gel mobility of secreted invertase, a protein exclusively N-glycosylated and thus a good reporter of Golgi N-glycosylation efficiency in vivo was analyzed in the absence and in the presence of increasing Ca 2+ concentrations (Fig. 1A) . In yeast, pmr1p is a Golgi Ca
2+
/Mn 2+ P-type ATPase that is involved in maintaining normal Golgi functions, such as glycosylation (21) (22) (23) . Thus, Pmr1Δ strains, known to produce and secrete an aberrant form of invertase, lacking high mannose residues, were taken as positive controls throughout our experiments (21, 23) . While invertase isolated from pmr1Δ strain migrates on native gels significantly faster than invertase isolated from a wild-type strain, no significant differences in the absence of Ca 2+ were observed between gdt1Δ and wild-type strains. Strikingly and in the However, since 0.5  CaCl 2 already leads to a strong invertase mobility defect in gdt1Δ strains, a 10 m CaCl 2 concentration was used. In these conditions, no glycosylation defect was observed in gdt1Δ strains, while in pmr1Δ strains 10 m CaCl 2 was sufficient to suppress the glycosylation defect ( Fig. 1A and C) . However, this low concentration was not sufficient to rescue the invertase mobility in the gdt1Δ/pmr1Δ double knock-out, demonstrating a crucial need for gdt1p in this rescue (Fig. 1C) . These unexpected findings not only demonstrate that the observed Golgi N-glycosylation defect in gdt1Δ strains cultured in the presence of high Ca 2+ concentrations can be suppressed by the addition of Mn 2+ but also that gdt1p is directly involved in the suppression of the glycosylation defect in the pmr1Δ strains supplemented with Ca 2+ . Altogether, one can ask the role of gdt1p
in Golgi Mn 2+ homeostasis.
Golgi manganese homeostasis is modified in TMEM165-deficient cell lines
In order to unravel the link between TMEM165, Golgi Mn 2+ homeostasis and Golgi glycosylation defects, TMEM165 expression was depleted using shRNA strategy in HeLa and HEK 293 cells. In order to avoid the issue of clonal variation, polyclonal populations of stably expressing cells were generated and used for the study. ShRNA depletion of TMEM165 in HeLa and HEK 293 cells was very efficient as 95% of TMEM165 was depleted compared with control cells ( Fig. 2A and C) . This decrease was also confirmed by immunofluorescence staining. As shown in Figure 2B and D, TMEM165 is absent in TMEM165-depleted cells.
To then assess the Mn 2+ Golgi homeostasis in TMEM165-depleted cells, we took advantage of the Golgi protein GPP130 that is known to be a specific Golgi Mn 2+ sensor (27, 28 TMEM165 knockdown provokes a glycosylation defect that can be suppressed by manganese supplementation
As we previously showed that Golgi glycosylation deficiency in gdt1Δ strains can be suppressed by the addition of MnCl 2 in the medium, we wanted to investigate in TMEM165-depleted cells (i) the glycosylation defect and (ii) the impact of Mn 2+ supplementation on the suppression of the glycosylation defect. To evaluate these two aspects, we first determined the steady-state glycosylation status of LAMP2, an extensively N-glycosylated lysosomal resident protein and TGN46, a glycoprotein known to be N-and O-glycosylated. For this, control and shTMEM165 HeLa and HEK293 cells were treated or not with MnCl 2 (Fig. 6) . While a subtle change in the LAMP2 mobility arguing for slight heterogeneity in glycosylation could be observed between control and shTMEM165 HeLa cells (Fig. 6A) , a more pronounced decrease in TGN46 molecular weight was observed compared with control cells (Fig. 6A) . Remarkably, when Mn 2+ was added to the cell culture, the altered gel mobility of LAMP2 and TGN46 was completely suppressed in shTMEM165 , were subjected to PNGase F treatment (Supplementary Material, Fig. S3 ). We found that deglycosylation of LAMP2 produced a 40 kDa polypeptide for both (Supplementary Material, Fig. S3A ). For TGN46 and in the absence of Mn 
Discussion
TMEM165 deficiency was recently found to lead to a type-II CDG associated with defective Golgi N-glycosylation. TMEM165/Gdt1p is extremely conserved during evolution, and has no known direct molecular function. TMEM165/Gdt1p is not directly involved in the Golgi glycosylation process, as it is neither a sugar transporter nor Ca 2+ concentrations in gdt1Δ led to strong N-glycosylation deficiencies while in pmr1Δ, the observed Golgi N-glycosylation defects were markedly suppressed in the presence of Ca 2+ . This antagonistic effect then implied different functions for these two proteins. Interestingly, previous work has also shown that the observed Golgi glycosylation defects in pmr1Δ were not due to the lack of Ca 2+ uptake but mainly to a lack of Mn 2+ uptake. Moreover, adding Mn 2+ to the culture medium can rescue the N-glycosylation defect of the pmr1Δ strains (22) . We therefore hypothesized that the observed glycosylation defect in gdt1Δ could also be linked to a decrease in Mn 2+ Golgi homeostasis. In that case, the addition homeostasis and Golgi galactosylation efficiency process (32) . Two Golgi galactosyltransferases are known to transfer Gal residues from UDP-Gal to terminal N-acetylglucosamine (GlcNAc) residues, the UDP-Gal:N-acetylglucosamine β-1,4-galactosyltransferase I (B4GALT1; EC 2.4.1.22) that synthesizes N-acetyl lactosamine structures on glycoproteins and the UDP-Gal:N-acetylglucosamine β-1,4-galactosyltransferase II (B4GALT2; EC 2.4.1.22) that both act on glycoproteins and glycolipids. From a general point of view, these enzymes as well as the Golgi glycosyltransferases using UDP-sugars as a donor substrate, absolutely require Mn 2+ for their activities. This could also explain why the GlcNAcylation process is also impaired in TMEM165-depleted HEK293 cells. Altogether, these experiments confirmed that in both yeasts and mammalian cells, the glycosylation abnormalities due to Gdt1p/TMEM165 defects are rescued by the addition of Mn 2+ .
In conclusion, we demonstrated that the observed Golgi glycosylation deficiencies in Gdt1p/TMEM165-deficient cells result from a defective Golgi Mn 2+ homeostasis. This study provides 
Material and Methods
Yeast strains and media , Difco). YPD media is a YEP media supplemented with 2% -glucose (SigmaAldrich). YPR is YEP supplemented with 2% raffinose (Euromedex). Selection antibiotics were added at 100 µg mL −1 for nourseothricine and 200 µg mL −1 for G418.
Invertase glycosylation analysis
Before any analysis, a preculture in YPD media is done and a volume equivalent to 15 OD600 nm units is centrifugated for 3 min at 3500 rpm. The supernatant is discarded and the pellet is resuspended in YPR media to induce invertase expression. Calcium, manganese and other ions were added at this step at the indicated concentration. After a 20 h culture in YPR, yeasts were centrifugated for 5 min at 3500 rpm. Supernatant was discarded and the pellet was kept frozen at −20°C. Invertase glycosylation analysis was performed as described by Ballou et al. (33) .
Antibodies and other reagents
Anti-TMEM165 and anti-β actin antibodies were from SigmaAldrich (St Louis, MO, USA). Anti-GM130 antibody was from BD Biosciences (Franklin lakes, NJ, USA). Anti-GPP130 antibody was purchased from Covance (Princeton, NJ, USA). Goat anti-rabbit or goat anti-mouse immunoglobulins HRP conjugated were purchased from Dako (Glostrup, Denmark). Polyclonal goat anti-rabbit or goat anti-mouse conjugated with Alexa Fluor was purchased from Thermo Fisher Scientific (Waltham, MA, USA). PNGase F was from Roche Diagnostics (GmbH, Penzberg, Germany). Other chemicals were from Sigma-Aldrich unless otherwise specified.
Cell culture and transfections
All cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS; Lonza, Basel, Switzerland), at 37°C in humidity-saturated 5% CO 2 atmosphere. We generated polyclonal HeLa and HEK293 stable cell lines knockdown for TMEM165 by the shRNA technique. Cells were transfected with the pGIPZ Lentiviral shRNA plasmid (Thermo Fisher Scientific) containing either shRNA sequences targeting TMEM165 mRNA or no sequences. The selection was done with puromycine. Thus, we generated two polyclonal cell lines, named control cell line and shTMEM165 for the cell line depleted in TMEM165. For manganese treatment, MnCl 2 was added for the times and concentrations described in each figures.
Immunofluorescence staining
Cells were seeded on coverslips for 12-24 h, washed once in Dulbecco's phosphate-buffered saline (DPBS, Lonza) and fixed either with 4% paraformaldehyde (PAF) in phosphate-buffered saline (PBS), pH 7.3, for 30 min at room temperature or with ice-cold methanol for 10 min at room temperature. Coverslips were then washed three times with PBS. Only if the fixation had been done with PAF, cells were permeabilized with 0.5% Triton X-100 in PBS for 15 min then washed three times with PBS. Coverslips were PNGase F deglycosylation assay 
Western blotting
Cells were scraped in DPBS and then centrifuged at 4500 rpm for 3 min. Supernatant was discarded and cells were then resuspended in RIPA buffer [Tris-HCl 50 m, pH 7.9, NaCl 120 m, NP40 0.5%, EDTA 1 m, Na 3 VO 4 1 m, NaF 5 m] supplemented with a protease cocktail inhibitor (Roche Diagnostics, Penzberg, Germany). Cell lysis was done by passing the cells several times through a syringe with a 26G needle. Cells were centrifuged for 30 min at 20 000 × g. The supernatant containing protein was estimated with the micro BCA Protein Assay Kit (Thermo Scientific). Twenty micrograms of total protein lysate were put in NuPAGE LDS sample buffer (Invitrogen), pH 8.4, supplemented with 4% β-mercaptoethanol (Fluka). Samples were heated 10 min at 95°C and then separated on 4-12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membrane Hybond ECL (GE Healthcare, Little Chalfont, UK). The membrane was blocked in blocking buffer (5% milk powder in TBS-T [1× TBS with 0.05% Tween 20]) for 1 h at room temperature, then incubated overnight with the primary antibodies in blocking buffer, and washed three times for 5 min in TBS-T. The membranes were then incubated with the peroxidase-conjugated secondary goat anti-rabbit or goat antimouse antibodies (Dako; used at a dilution of 1:10 000) in blocking buffer for 1 h at room temperature and later washed three times for 5 min in TBS-T. Signal was detected with chemiluminescence reagent (ECL 2 Western Blotting Susbtrate, Thermo Scientific) on imaging film (GE Healthcare, Little Chalfont, UK).
Glycan analysis by mass spectrometry
Cells were sonicated in extraction buffer (25 m Tris, 150 m NaCl, 5 m EDTA and 1% CHAPS, pH 7.4) and then dialyzed in 6-8 kDa cut-off dialysis tubing in an ammonium bicarbonate solution (50 m, pH 8.3) for 48 h at 4°C and lyophilized. The proteins/glycoproteins were reduced and carboxyamidomethylated followed by sequential tryptic and peptide N-glycosidase F digestion and Sep-Pak purification. Permethylation of the freeze-dried glycans and MALDI-TOF-MS of permethylated glycans were performed as described elsewhere (34) .
Statistical analysis
Comparisons between groups were performed using Student's t-test for two variables with equal or different variances, depending on the result of the F-test.
